A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Clinical trial NCT06728410 · RECRUITING

Trial details

NCT number: NCT06728410
Sponsor: Mehmet Akce
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Intrahepatic Cholangiocarcinoma FGFR2 Gene Rearrangement FGFR2 Gene Mutation

Start date: 2026-01-27
Primary completion: 2026-07-01
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.